Richard Roths Media Announces $52 Million Dollar Investment Approval to Expand its AI-Driven Marketing Systems
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year
Reco Mitigates AI Agent Risk Across Claude and the Enterprise
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results
Hoppn Shop by Color Search Technology is Available to Shopify Merchants
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision…
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision…
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis”…
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis”…
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing…
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing…
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody…
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody…
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining…
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining…
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the…
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the…
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for…
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for…
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…